Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20004 in Type 2 Diabetes
NCT03848793Phase 2Completed
- Sponsor
- Hengrui
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of noiiglutide in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Hengrui. Primary endpoint: Glycated Hemoglobin at 16 weeks. Started Mar 2019; status: completed.
02
Drugs
noiiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03848793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848793.